BDBM295670 (S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3-yl)-5,6- dihydrobenzo[f]imidazo[1,2- d][1,4]oxazepin-9- yl)amino)propanamide::US10112932, Compound 106::US10851091, Compound 106

SMILES C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@H](CF)COC1=O)C(N)=O

InChI Key InChIKey=IRTAFDFALCVEOW-CMPLNLGQSA-N

Data  8 KI

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 295670   

LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  0.0400nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 3-kinase regulatory subunit alpha(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  0.0400nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  16.7nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  16.7nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  17.8nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  17.8nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPhosphatidylinositol 3-kinase regulatory subunit beta(Homo sapiens (Human))
Genentech

US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  122nMAssay Description:PI3K Binding assays are intended for determining the biochemical potency of small molecule PI3K inhibitors. The PI3K lipid kinase reaction is perform...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
LigandPNGBDBM295670((S)-2-((2-((S)-4-(fluoromethyl)-2- oxooxazolidin-3...)
Affinity DataKi:  122nMAssay Description:The biochemical inhibition of four PI3K isoforms by the Formula I compounds of Table 1. In addition, two clinically tested PI3K compounds, taselisib ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent